p53-based immunotherapy of cancer

Critical Reviews in Immunology

Volumn 18, Issue 1-2, 1997, Pages 29-35

  Deleo, Albert B ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Anti self; CTL; Dendritic cells; Epitopes; Tumor antigens; Vaccines

Indexed keywords

CANCER VACCINE; HLA ANTIGEN; PROTEIN P53;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CONFERENCE PAPER; CROSS REACTION; DENDRITE; GENE TARGETING; HOST RESISTANCE; HUMAN; MISSENSE MUTATION; NONHUMAN; PRIORITY JOURNAL; SARCOMA; TUMOR SUPPRESSOR GENE;

ANIMALS; AUTOIMMUNITY; DISEASE MODELS, ANIMAL; FORECASTING; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030669142     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. DeLeo, A. B., Jay, G., Appella, E., DuBois, G. C., Law, L. W., and Old, L. J., Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse, Proc. Natl. Acad. Sci. U.S.A., 76, 2420, 1979.
2. DeLeo, A. B., Shiku, H., Takahashi, T., John, M., and Old, L. J., Cell surface antigens of chemically induced sarcomas of the mouse. I. MuLV-related antigens and alloantigens on cultured-fibroblasts and sarcoma cells. Description of a unique antigen on transplanted Meth A sarcoma, J. Exp. Med., 146, 720, 1977.
3. Hollstein, M. D., Sidransky, D., Vogelstein, B., and Harris, C. C., p53 Mutations in human cancers, Science, (Wash. DC), 253, 49, 1991.
4. Houghton, A., Cancer antigens: immune recognition of self and altered self, J. Exp. Med., 180, 1, 1994.
5. Falk, K., Rotzschke, O., Stevanovic, S., Jung, G., and Rammensee, H. G., Allele-specific motifs revealed by sequencing of self peptides eluted from MHC molecules, Nature (London), 351, 290, 1991.
6. Widenfeld, E. A., Fernadez-Vina, M., Berzofsky, J. A., and Carbone, D. P., Evidence for selection against human lung cancers bearing p53 missense mutations which occur within HLA A*0201 peptide consensus motif, Cancer Res., 54, 1175, 1994.
7. Houbiers, J. G. A., Nijman, H. W., van der Burg, S. W., Drijfhout, J. W., Kenemans, P., van de Velde, C. J. H., Brand, A., Momborg, F., Kast, W. M., and Melief, C. J. M., In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53, Eur. J. Immunol., 23, 2072, 1993.
8. Garrido, F., Ruiz-Cabello, F., Cabrera, T., Perez-Villar, J. J., Lopez-Botet, M., Buggan-Keen, M., and Stern, P. L., Implications for immunosurveillance of altered HLA class I phenotypes in human tumours, Immunol. Today, 18,89, 1997.
9. Chung, K. Y., Mukhopadhyay, T., Kim, J., Casson, A., Ro, J. V., Goepfert, H., Ho, W. K., and Roth, J. A., Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract, Cancer Res., 53, 1676, 1993.
10. Levine, A., p53, the cellular gatekeeper for growth and division, Cell, 88, 323, 1977.
11. Crawford, L. V., Pim, D. C., and Bulbrook, R. D., Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer, Int. J. Cancer, 30, 403, 1982.
12. Soussi, T., The humoral response to the tumor-suppressor gene product p53 in human cancer: implication for diagnosis and therapy, Immuunol. Today, 17, 353, 1996.
13. Tilkin, A-F., Lubin, R., Soussi, T., Lazar, V. Janin, N., Mathieu, M-C., Lefrere, I., Carlu, C., Roy, M., Kayibanda, M., Bellet, D., Guillet, J-G., and Bressac-de Paillerets, B., Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer, Eur. J. Immunol., 25, 1765, 1995.
14. Zeh, H. J., Leder, G. H., Lotze, M. T., Salter, R. D., Tector, M., Stuber, G., Modrow, S., and Storkus., W. J., Flow-cytometric determination of peptide-class I complex formation. Identification of p53 peptides that bind to HLA-A2, Human Immunol., 39, 79, 1994.
15. Theobald, M., Biggs, J., Dittmer, D., Levine, A. J., and Sherman, L. A., Targeting p53 as a general tumor antigen, Proc. Natl. Acad. Sci. U.S.A., 92, 11993, 1995.
16. Ropke, M., Hald, J., Guldberg, P., Zeuthen, J., Norgaard, L., Fugger, L., Sveigarrd, S., van der Burg, S., Nijman, H. W., Melief, C. J. M., and Claesson, M. H., Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide, Proc. Natl. Acad. Sci. U.S.A., 93, 14704, 1996.
17. Theobald, M., Biggs, J., Hernadez, J., Lustgarten, J., Labadie, C., and Sherman, L. A., Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes, J. Exp. Med., 185, 833, 1997.
18. Noguchi, Y, Chen, Y-T, and Old, L. J., A mouse mutant p53 product recognized by CD4+ and CD8+ T cells, Proc. Natl. Acad. Sci. U.S.A., 91, 3171, 1996.
19. Mayordomo, J. I., Zorina, T., Storkus, W. J., Celluzzi, C., Falo, L., Kast, W. M., Ildstad, S. T., DeLeo, A. B., and Lotze, M. T., Bone marrowderived dendritic cells pulsed with tumor peptides elicit protective and therapeutic anti-tumor immunity, Nature Med., 1, 1298, 1995.
20. Mayordomo, J. I., Loftus, D. J., Sakamoto, H. J., DeCesare, C. M., Appasamy, P. M., Lotze, M. T., Storkus, W. J., Appella, E., and De Leo, A. B., Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines, J. Exp. Med., 183, 1357, 1996.
21. Ikeda, H., Ohta, N., Furukawa, K., Miyazaki, H., Wang, L., Furukawa, K., Kuribayashi, K., Old, L. J., and Shiku, H., Mutated MAP kinase: a tumor rejection antigen of mouse sarcoma, Proc. Natl. Acad. Sci. U.S.A., 94, 6375, 1997.
22. Jay, G., DeLeo, A. B., Appella, G., Du Bois, G. C., Law, L. W., Khoury, G., and Old, L. J., A common transformation-related protein in murine sarcomas and leukemias, Cold Spring Harbor Symp. Quant. Biol., 44, 659, 1980.
23. Dahl, A. M., Beverley, P. C. L., and Stauss, H. J., A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoractive, high-avidity cytotoxic T lymphocytes that recognize naturally processed protein, J. Immunol., 157, 239, 1996.
24. Lacabanne, V., Viguier, M., Guillet, J-G., and Choppin, J. A., Wild-type p53 cytotoxic T cell epitope is presented by mouse hepatocarcinoma cells, Eur. J. Immunol., 26, 2635, 1996.
25. Kubo, R., Sette, A., Grey, H. M., Appella, E., Sakaguchi, K., Zhu, N-Z., Arnott, D., Sherman, N., Shabanowitz, J., Michel, H., Bodnar, W. M., Davis, T. A., and Hunt, D. F., Definition of specific peptide motifs for four major HLA-A alleles, J. Immunol., 152, 3913, 1994.
26. Roth, J., Dittmer, D., Rea, L., Tartaglia, J., Paoletti, E., and Levine, A. J., p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge, Proc. Natl. Acad. Sci. U.S.A., 93, 4781, 1996.
27. Clayman, G. L., El-Nagger, A. K., Roth, J. A., Zhang,W-W., Goepfert, H., Taylor, D. L., and Liu, T-J., In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma, Cancer Res., 55, 1, 1995.
28. Roth, J. A., Nguyen, D., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., Ferson, D. Z., Hong, W. K., Komaki, R., Lee, J. J., Nesbitt, J. C., Pisters, K. M. W., Putnam, J. B., Schea, R., Shin, D. M., Walsh, G. L., Dolormente, M. M., Han, D-I., Marin, F. D., Yen, N., Xu, K., Stephens, L. C., McDonnell, T. J., Mukhopadhyay, T., and Cai, D., Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer, Nature Med., 9, 985, 1996.
29. Tahara, H., Zitvogen, L, Storkus, W. J., Elder, E. M., Kinzler, D., Whiteside, T. L., Robbins, P. D., and Lotze, M. T., Phase I clinical trial of interleukin12 (IL-12) gene therapy using direct injection of tumors with genetically engineered fibroblasts, Proc. ASCO, 15, 235(579), 1996.